BiotechTube
Home/Pipeline/KEYTRUDA (pembrolizumab)

KEYTRUDA (pembrolizumab)

Adjuvant Non-Small Cell Lung Cancer (NSCLC)

Phase 3Active, Regulatory Review

Key Facts

Indication
Adjuvant Non-Small Cell Lung Cancer (NSCLC)
Phase
Phase 3
Status
Active, Regulatory Review
Company
Merck, Merck

About Merck

Merck & Co. is a research-intensive biopharmaceutical giant with a foundational mission to put medicine before profits, driving global health impact. Its strategic focus is on high-growth therapeutic areas, most notably oncology led by blockbuster KEYTRUDA, complemented by a robust vaccine portfolio and promising pipeline. The company leverages a multi-modal technology platform and significant financial strength to sustain innovation, navigate patent cliffs, and pursue strategic business development to fuel long-term growth.

View full company profile

About Merck

Merck & Co. is a research-intensive biopharmaceutical giant with a foundational mission to put medicine before profits, driving global health impact. Its strategic focus is on high-growth therapeutic areas, most notably oncology led by blockbuster KEYTRUDA, complemented by a robust vaccine portfolio and promising pipeline. The company leverages a multi-modal technology platform and significant financial strength to sustain innovation, navigate patent cliffs, and pursue strategic business development to fuel long-term growth.

View full company profile

Therapeutic Areas

OncologyVaccinesImmunologyCardiometabolicInfectious DiseasesNeuroscience